Japan assesses the innovation level of medical devices by evaluating their clinical benefits, uniqueness, and improvements over existing technologies. Chuikyo and MHLW review evidence demonstrating safety, efficacy, and cost-effectiveness. Devices offering significant advancements in patient outcomes, treatment efficiency, or healthcare impact may... Read More
Japan uses bundled payments for certain medical procedures, including associated devices, under the Diagnosis Procedure Combination (DPC) system. This system integrates device costs into overall procedure reimbursement, encouraging cost-efficiency. Bundled payments apply to standardized treatments, while high-cost or innovative devices may still... Read More
Reimbursement decisions significantly impact market access in Japan by determining a medical device’s affordability and adoption under the NHI system. Positive decisions enable widespread use in the healthcare system, while unfavorable outcomes may limit market entry. Pricing, classification, and alignment with NHI... Read More
Japan’s reimbursement system evaluates wearable medical devices based on clinical efficacy, safety, and cost-effectiveness. MHLW and Chuikyo determine classification and pricing under the NHI system. Wearables must demonstrate measurable health benefits and align with healthcare needs. Innovative wearables offering significant improvements in... Read More
Cutting-edge devices in Japan may qualify for special reimbursement criteria, such as the Premium for New Technology. To qualify, devices must demonstrate significant clinical innovation, improved patient outcomes, or cost-effectiveness beyond existing technologies. MHLW and Chuikyo evaluate robust evidence during the reimbursement... Read More
Japan reimburses single-use medical devices based on their classification, clinical benefits, and cost-effectiveness under the NHI system. Pricing is determined by Chuikyo, considering manufacturing costs and healthcare impact. Reimbursement encourages cost control while ensuring patient safety. Innovative single-use devices may qualify for... Read More
In Japan, reimbursement submission timelines depend on the device’s classification and regulatory approval. Applications to MHLW are typically submitted post-PMDA approval. The review process by Chuikyo usually takes 6-12 months. Timelines may extend for innovative or novel devices requiring new categories or... Read More
Japan evaluates the economic impact of medical devices through cost-effectiveness analysis, often using metrics like quality-adjusted life years (QALYs) and cost-benefit ratios. Chuikyo and MHLW assess how devices improve healthcare outcomes while controlling costs. Evidence of long-term savings, efficiency, and value compared... Read More
Clinical evidence plays a critical role in Japan’s reimbursement process, demonstrating a medical device’s safety, efficacy, and clinical benefits. MHLW and Chuikyo use this evidence to assess the device’s therapeutic value, cost-effectiveness, and alignment with NHI criteria. Robust clinical data, including trial... Read More
Combination drug-device products in Japan are reimbursed based on their primary mode of action, as determined by MHLW. If the drug is primary, the product follows pharmaceutical reimbursement rules; if the device is primary, it follows medical device rules. Chuikyo evaluates clinical... Read More